Alpha Teknova (TKNO) Liabilities and Shareholders Equity (2020 - 2026)
Alpha Teknova (TKNO) posted quarterly Liabilities and Shareholders Equity of $98.7 million for Q1 2026, down 13.45% year-over-year from $114.0 million in Q1 2025, and down 4.76% quarter-over-quarter from $103.6 million in Q4 2025.
Alpha Teknova (TKNO) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Alpha Teknova (TKNO) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $98.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 13.45% year-over-year to $98.7 million; the TTM figure through Mar 2026 stood at $420.4 million (down 10.98% YoY), while the FY2025 annual figure was $103.6 million, down 12.79% from the prior year.
- Liabilities and Shareholders Equity declined to $98.7 million in Q1 2026 per TKNO's latest filing, from $103.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $184.1 million in Q1 2022 and bottomed at $98.7 million in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $131.3 million across 5 years, with a median of $124.1 million in 2024.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity gained 5.58% — and 2023, when it fell 27.25%.
- Alpha Teknova's Liabilities and Shareholders Equity stood at $152.3 million in 2022, then retreated by 15.55% to $128.6 million in 2023, then declined by 7.64% to $118.8 million in 2024, then dropped by 12.79% to $103.6 million in 2025, then retreated by 4.76% to $98.7 million in 2026.
- Business Quant data shows TKNO's Liabilities and Shareholders Equity at $98.7 million in Q1 2026, $103.6 million in Q4 2025, and $107.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Alpha Teknova | 396.90 Mn | 379.46 Mn | 4.89 Mn | 95.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.88 Mn |
| Mar 31, 2026 | 98.66 Mn |
| Dec 31, 2025 | 103.58 Mn |
| Sep 30, 2025 | 107.63 Mn |
| Jun 30, 2025 | 110.49 Mn |
| Mar 31, 2025 | 113.99 Mn |
| Dec 31, 2024 | 118.77 Mn |
| Sep 30, 2024 | 124.10 Mn |
| Jun 30, 2024 | 115.35 Mn |
| Mar 31, 2024 | 120.82 Mn |
| Dec 31, 2023 | 128.59 Mn |
| Sep 30, 2023 | 138.39 Mn |
| Jun 30, 2023 | 132.55 Mn |
| Mar 31, 2023 | 141.02 Mn |
| Dec 31, 2022 | 152.26 Mn |
| Sep 30, 2022 | 160.27 Mn |
| Jun 30, 2022 | 182.20 Mn |
| Mar 31, 2022 | 184.08 Mn |
| Dec 31, 2021 | 166.51 Mn |
| Sep 30, 2021 | 169.16 Mn |